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The aim of the present study was to evaluate the effect of cotrimoxazole on the in vitro susceptibility of Coccid-
ioides posadasii strains to antifungals. A total of 18 strains of C. posadasii isolated in Brazil were evaluated in this 
study. The assays were performed in accordance with the Clinical and Laboratory Standards Institute guidelines 
and the combinations were tested using the checkerboard method. The minimum inhibitory concentrations were 
reduced by 11, 2.4, 4.3 and 3.5 times for amphotericin B, itraconazole, fluconazole and voriconazole, respectively. 
Moreover, it was seen that cotrimoxazole itself inhibited C. posadasii strains in vitro. The impairment of folic acid 
synthesis may be a potential antifungal target for C. posadasii. 
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In the recent years, several studies have shown the 
antifungal effect of “non-antifungal drugs” against true 
pathogenic species (Afeltra & Verweij 2003, Chapman et 
al. 2008, Cordeiro et al. 2009). The search for new an-
tifungals is warranted because of the limited number of 
therapeutic drugs available for treating these infections. 
In addition, many researchers have been trying to im-
prove the results obtained with antifungal monotherapy. 
Although data from controlled clinical trials are scarce, 
many recent reports have claimed beneficial effects of an-
tifungal combinations for the treatment of severe fungal 
infections (Johnson & Perfect 2010, Matsuda et al. 2010).
Coccidioidomycosis is a deep fungal infection 
caused by the soil-dwelling ascomycetes Coccidioides 
spp. The disease has a broad clinical spectrum, ranging 
from a mild respiratory syndrome to progressive pneu-
monia and meningitis (Galgiani et al. 2005). Although 
Coccidioides spp rarely display antifungal resistance 
in vitro (Kriesel et al. 2008), specialists recognise that 
coccidioidomycosis is one of the most refractory fungal 
infections (Stevens et al. 2007). Therefore, several in vitro 
and in vivo studies have been performed in an attempt 
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to identify new potential therapeutic drugs and anti-
microbial combinations that can be used against Coc-
cidioides spp (Shubitz et al. 2006, González et al. 2007, 
Cordeiro et al. 2009). 
In this study, we investigated the effect of cotrimox-
azole - a wide-spectrum antimicrobial formed by sulfame-
thoxazole (SMX) plus trimethoprim (TMP) - on the in 
vitro susceptibility of Coccidioides posadasii to ampho-
tericin B (AMB), currently the most important drug used 
to treat life-threatening forms of coccidioidomycosis. 
A total of 18 strains of C. posadasii isolated in the 
state of Ceará (Northeast Brazil) from clinical (n = 15) 
and environmental (n = 3) sources were evaluated in this 
study. The strains of C. posadasii were obtained from 
storage in 0.9% saline at 4ºC, subcultured on Sabouraud 
glucose agar (Difco, Detroit, USA) and incubated at 
25ºC for 10 days. Prior to antimicrobial testing, the vi-
ability and purity of each isolate were evaluated by mi-
croscopic examinations and polymerase chain reaction 
experiments described elsewhere (Cordeiro et al. 2010). 
All procedures were performed within a class II biologi-
cal safety cabinet in a biosafety level 3 laboratory.
Stock solutions of AMB (Sigma Chemical Co, USA), 
itraconazole (ITR) (Janssen Pharmaceutica, Belgium) 
and voriconazole (VRZ) (Pfizer Pharmaceuticals, USA) 
were prepared in dimethyl sulfoxide (Sigma Chemical 
Co, USA). Fluconazole (FLC) (Pfizer Pharmaceuti-
cals, USA) was prepared in distilled water according to 
Clinical and Laboratory Standards Institute (CLSI 2008) 
SMX plus TMP (Hipolabor Ind Farmacêutica Ltda, Bra-
zil) and SMX/TMP/AMB combinations were prepared 
in Roswell Park Memorial Institute (RPMI) 1640 me-
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dium with L-glutamine and without sodium bicarbonate 
(Sigma Chemical Co, St. Louis, MO, USA) and buffered 
with 0.165 M MOPS (Sigma Chemical Co, USA). Serial 
two-fold dilutions of each antimicrobial combination 
were performed in RPMI 1640 medium.
Inoculum preparation was carried out as described by 
Cordeiro et al. (2009). Sterile normal saline was added 
to each agar slant and the cultures were gently scraped 
with cotton swabs. The suspension was transferred to 
a sterile tube and allowed to settle for 5 min and then 
the transmittance of the upper homogeneous supernatant 
was read at 530 nm and adjusted to 95% transmittance. 
The suspension containing arthroconidia and hyphae 
was diluted 1:10 with RPMI 1640 medium containing L-
glutamine and without sodium bicarbonate and buffered 
to pH 7.0 with 0.165 M MOPS to obtain an inoculum of 
approximately 1 x 103-5 x 103 CFU/mL.
Antifungal susceptibility assays were performed by 
the broth macrodilution method (M38-A2) according 
to CLSI (2008) standards guidelines. First, the strains 
were tested against each antimicrobial alone to deter-
mine the minimum inhibitory concentrations (MICs). 
The drug concentration ranges tested were as follows: 
AMB, 0.0625-1.0 μg/mL; ITR, 0.0625-1.0 μg/mL; VRZ, 
0.031-0.5 μg/mL; FLC, 0.78-12.5 μg/mL; SMX-TMP, 
250/50-4,000/800 μg/mL. The procedures were repeated 
at least twice and each fungal strain was tested in dupli-
cate. MICs for AMB and azoles were defined as the low-
est concentration of the drug at which there was no vis-
ible fungal growth (CLSI 2008). We defined the MIC of 
SMX/TMP as the lowest drug concentration that caused 
80% inhibition of visible fungal growth. After MIC defi-
nition for each drug, the strains were tested against the 
combination AMB/SMX/TMP. The following concen-
trations were tested: AMB, 0.007-0.116 µg/mL; SMX/
TMP, 125/25-2,000/400 µg/mL. The MIC of each drug 
in combination was defined as the lowest concentration 
that caused 80% inhibition of visible fungal growth. 
The non-parametric Wilcoxon Signed Rank Test was 
used for analysis of the antimicrobial combinations. The 
results were expressed as the mean and a p value of < 
0.05 was considered significant.
TABLE I
Minimum inhibitory concentration (MIC) of sulfamethoxazole plus trimethoprim (SMX/TMP)  
and antifungals against clinical and environmental Coccidioides posadasii strains
Strain
MIC (µg/mL)
AMB ITR FLC VRZ SMX/TMP
Clinical source
01-6-085 0.125 0.125 3.125 0.125 1,000/200
01-6-087 0.125 0.125 3.125 0.125 2,000/400
01-6-088 0.125 0.125 3.125 0.125 2,000/400
01-6-089 0.125 0.125 3.125 0.125 2,000/400
01-6-101 0.0625 0.125 6.25 0.125 2,000/400
01-6-102 0.125 0.125 6.25 0.125 2,000/400
01-6-103 0.125 0.5 6.25 0.125 1,000/200
05-02-063 0.125 0.125 6.25 0.25 2,000/400
05-02-064 0.125 0.25 6.25 0.25 2,000/400
05-02-065 0.125 0.125 6.25 0.125 2,000/400
05-02-066 0.0625 0.25 6.25 0.25 2,000/400
05-02-067 0.125 0.125 3.125 0.125 2,000/400
05-02-068 0.125 0.125 6.25 0.125 1,000/200
05-02-069 0.125 0.125 6.25 0.125 1,000/200
05-02-070 0.0625 0.125 6.25 0.125 2,000/400
Environmental source
01-6-090 0.125 0.25 6.25 0.125 2,000/400
01-6-091 0.125 0.125 3.125 0.125 2,000/400
01-6-092 0.125 0.125 6.25 0.125 2,000/400
Geometric mean 0.111 0.151 4.961 0.140 1714.48/342.89
AMB: amphotericin B; FLC: fluconazole; ITR: itraconazole; VRZ: voriconazole.
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TABLE II
Minimum inhibitory concentration (MIC) of sulfamethoxazole plus trimethoprim (SMX/TMP)  
associated with antifungals against clinical and environmental Coccidioides posadasii strains
Strains
MIC (µg/mL)
SMX/TMP + AMB SMX/TMP + ITR SMX/TMP + FLC SMX/TMP + VRZ
01-6-085 250/50 0.007 250/50 0.062 250/50 0.781 500/100 0.062
01-6-087 500/100 0.015 500/100 0.125 250/50 0.781 250/50 0.031
01-6-088 500/100 0.015 500/100 0.125 500/100 1.562 250/50 0.031
01-6-089 500/100 0.015 250/50 0.062 250/50 0.781 250/50 0.031
01-6-090 500/100 0.015 500/100 0.125 500/100 1.562 500/100 0.062
01-6-091 500/100 0.015 250/50 0.062 500/100 1.562 500/100 0.062
01-6-092 500/100 0.015 250/50 0.062 250/50 0.781 250/50 0.031
01-6-101 500/100 0.015 500/100 0.125 500/100 1.562 500/100 0.062
01-6-102 1,000/200 0.031 250/50 0.062 500/100 1.562 500/100 0.062
01-6-103 500/100 0.015 250/50 0.062 500/100 1.562 250/50 0.031
05-02-063 500/100 0.015 250/50 0.062 250/50 0.781 250/50 0.031
05-02-064 500/100 0.015 250/50 0.062 250/50 0.781 250/50 0.031
05-02-065 1,000/200 0.031 500/100 0.125 250/50 0.781 500/100 0.062
05-02-066 500/100 0.015 250/50 0.062 500/100 1.5625 250/50 0.031
05-02-067 500/100 0.015 500/100 0.125 500/100 1.562 500/100 0.062
05-02-068 500/100 0.015 250/50 0.062 250/50 0.781 250/50 0.031
05-02-069 500/100 0.015 250/50 0.062 250/50 0.781 250/50 0.031
05-02-070 1,000/200 0.031 250/50 0.062 500/100 1.562 500/100 0.062
AMB: amphotericin B; FLC: fluconazole; ITR: itraconazole; VRZ: voriconazole.
The MIC (geometric means) was 0.111 µg/mL, 
0.155 µg/mL, 4.819 µg/mL and 0.142 µg/mL for AMB, ITR, 
FLC and VRZ, respectively. The antimicrobial combina-
tion SMX/TMP was also able to inhibit the growth of all 
C. posadasii strains in vitro and the MIC values ranged 
from 1,000/200-2,000/400 μg/mL (Table I). When used in 
combination with SMX/TMP, the MICs of the antifungals 
were reduced by 11, 2.4, 4.3 and 3.5 times for AMB, ITR, 
FLC and VRZ, respectively (p < 0.05) (Table II). Sulpha 
derivatives are antimetabolic drugs that impair folic acid 
synthesis in microorganisms. These compounds have 
a broad antimicrobial spectrum and are active against 
several aerobic bacteria and some protozoan species and 
these compounds are frequently used successfully for 
the treatment and prevention of pneumonia caused by 
Pneumocystis jiroveci in acquired immune deficiency 
syndrome patients (Thomas et al. 2009). Although these 
compounds are not common first-line drugs in the man-
agement of fungal infections, the combination of SMX/
TMP has shown good results in treating paracoccid-
ioidomycosis (Hahn et al. 2003, Wanke & Aidê 2009). 
Our results show that SMX/TMP was able to enhance the 
susceptibility of C. posadasii to AMB by reducing the 
AMB MIC by approximately 5.85 times. Surprisingly, it 
was shown that the combination SMX/TMP alone was 
also able to impair C. posadasii growth in vitro. 
In a previous work, Hanafy et al. (2007) found a 
great variability among SMX MICs against Cryptococ-
cus sp. The authors reported that higher MIC values 
were attained when susceptibility tests were performed 
in organic-rich media because para-aminobenzoic acid 
(PABA) or PABA-related compounds may be present. In 
this study, we tried to perform the susceptibility tests 
with yeast nitrogen base, as suggested by Hanafy et al. 
(2007), but unfortunately this medium did not support 
the growth of C. posadasii (data not shown). Because 
other studies have already been performed with RPMI 
(Yekutiel et al. 2004, Navarro-Martinez et al. 2006), we 
decided to evaluate this medium in our experiments. 
However, we assumed that in PABA-free medium, SMX/
TMP may cause a greater reduction in AMB MICs. 
We hypothesise that low concentrations of AMB 
may have caused slight damage to the fungal plasmatic 
membrane, allowing moderate ion leakage. In addition, 
these channels across the membrane may have allowed 
SMX/TMP to enter the cell. Therefore, we believe that 
acid folic blockade may be a potential target for C. posa-
dasii inhibition. The design of sulpha drugs with higher 
affinity for dihydrofolate reductase or other folic acid 
biosynthetic pathway enzymes could enhance fungal in-
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hibition. In fact, this pathway seems to be determinant 
of fungal viability, as Aspergillus fumigatus mutants 
defective in folate biosynthesis have been shown to be 
avirulent (Brown et al. 2000).
According to Navarro-Martinez et al. (2006), in-
terruption of the folic acid biosynthetic pathway also 
impairs ergosterol production in Candida albicans, 
possibly by disturbing the metabolism of sterol C24 
methyltransferase because the synthesis of its substrate 
is also blocked. It is well-known that ergosterol biosyn-
thesis is also interrupted by azole antifungals agents that 
act on sterol 14 α-demethylase enzyme. The synergistic 
effect of these drugs was demonstrated in this study. 
Although it is reasonable to suppose that the results 
of susceptibility tests against the parasitic form of C. 
posadasii are more reliable, very few studies have tested 
the susceptibility pattern of the yeast-like form of the 
fungus because the transition from mycelia to yeast it is 
not easily achieved (Hector et al. 1988). In contrast, tests 
with cells in the saprophytic phase are easier to perform 
and, even though CLSI protocols are not intended for 
testing dimorphic fungi, these protocols can be applied, 
generating results that are easy to compare.
The results obtained in this study demonstrate the 
potential of the SMX/TMP/AMB combination, which 
has an inhibitory effect on C. posadasii strains, even at 
sub-MIC concentrations of AMB. In addition, the results 
showed that SMX/TMP also has an inhibitory effect on 
C. posadasii, suggesting that acid folic blockade may be 
a potential antifungal target for C. posadasii. As far as 
we know, this is the first report of the antifungal poten-
tial of sulpha drugs against this pathogen.
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